Pharma

Partner Content
Kantar_ASCO Day 5 coverage pic
Partner Content

Ibrance approval cemented as competition comes into view

In February 2015,  Pfizer's Ibrance (palbociclib) was granted accelerated approval by the FDA for treatment of newly diagnosed HR+ (hormone receptor positive) / HER2- breast cancer in post-men

Partner Content
Kantar_ASCO Day 3 coverage pic
Partner Content

Further Darzalex results extend hope for PFS in Myeloma

Earlier this year (March), Johnson & Johnson announced that the randomized Phase III CASTOR trial (NCT02136134) achieved its primary endpoint and was stopped early as recommended by the Indepen